Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
NCT00849290
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
113
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Androgen Independent Prostate Cancer
Interventions
BIOLOGICAL:
APC8015F
Sponsor
Dendreon